Korean Circulation Journal

  • 제44권1호
  • /
  • Pages.54-58
  • /
  • 2014
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Two Cases of Super-Giant Coronary Aneurysms after Kawasaki Disease

  • Lee, Joowon (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Kim, Gi Beom (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Kwon, Bo Sang (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Bae, Eun Jung (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Noh, Chung Il (Department of Pediatrics, Seoul National University Children's Hospital)
  • 투고 : 2013.06.10
  • 심사 : 2013.09.10
  • 발행 : 2014.01.30
⟨ 이전 논문 다음 논문 ⟩

초록

Acute giant coronary aneurysm after Kawasaki disease (KD) is a catastrophic complication that can be fatal and very difficult to manage. However, no fixed consensus has been reached for the management of super-giant coronary aneurysms in the acute setting. Here, we report the successful management of young children with super-giant coronary aneurysms after KD. Based on our experience, hemodynamic stabilization to prevent further coronary dilation or rupture and strict anticoagulation to avoid thrombus formation are mandatory in the management of this condition.

키워드

참고문헌

  1. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics 2000;106:E27. https://doi.org/10.1542/peds.106.2.e27
  2. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44. https://doi.org/10.1016/S0140-6736(04)16814-1
  3. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. https://doi.org/10.1161/01.CIR.94.6.1379
  4. Suda K, Kudo Y, Higaki T, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J 2009;73: 1319-23. https://doi.org/10.1253/circj.CJ-08-0931
  5. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22:79-85. https://doi.org/10.2188/jea.JE20110131
  6. McNeal-Davidson A, Fournier A, Scuccimarri R, et al. The fate and observed management of giant coronary artery aneurysms secondary to Kawasaki disease in the Province of Quebec: the complete series since 1976. Pediatr Cardiol 2013;34:170-8. https://doi.org/10.1007/s00246-012-0409-2
  7. Suzuki N, Seguchi M, Kouno C, Inukai K, Kito H, Kobayashi H. Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int 1999;41:318-20. https://doi.org/10.1046/j.1442-200x.1999.01058.x
  8. Imai Y, Sunagawa K, Ayusawa M, et al. A fatal case of ruptured giant coronary artery aneurysm. Eur J Pediatr 2006;165:130-3. https://doi.org/10.1007/s00431-005-0016-9
  9. Panzer J, De Jaeger A, Suys B. Rupture of giant coronary arterial aneurysm without progressive dilation. Cardiol Young 2008;18:189-90.
  10. Sunagawa K, Mitsumata M, Ayusawa M, Kusumi Y. Ruptured giant aneurysm of the left anterior descending coronary artery in Kawasaki disease. Pediatr Cardiol 2008;29:1115-9. https://doi.org/10.1007/s00246-008-9236-x
  11. Kuramochi Y, Ohkubo T, Takechi N, Fukumi D, Uchikoba Y, Ogawa S. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr Int 2000;42:470-5. https://doi.org/10.1046/j.1442-200x.2000.01270.x
  12. Ohkubo T, Fukazawa R, Ikegami E, Ogawa S. Reduced shear stress and disturbed flow may lead to coronary aneurysm and thrombus formations. Pediatr Int 2007;49:1-7. https://doi.org/10.1111/j.1442-200X.2007.02312.x
  13. Kato H, Inoue O, Ichinose E, Akagi T, Sato N. Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction. Acta Paediatr Jpn 1991;33:27-35. https://doi.org/10.1111/j.1442-200X.1991.tb01516.x
  14. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
  15. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379:1613-20. https://doi.org/10.1016/S0140-6736(11)61930-2
  16. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99:76-82. https://doi.org/10.1136/heartjnl-2012-302126
  17. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001; 43:211-7. https://doi.org/10.1046/j.1442-200x.2001.01373.x

피인용 문헌

  1. Giant coronary artery aneurysms complicating Kawasaki disease in Mexican children vol.28, pp.3, 2014, https://doi.org/10.1017/s1047951117001470
  2. Relapse of nephrotic syndrome triggered by Kawasaki disease vol.7, pp.1, 2014, https://doi.org/10.1007/s13730-017-0282-1
  3. Lymph-node-first Kawasaki disease and giant coronary artery aneurysm vol.12, pp.2, 2019, https://doi.org/10.1136/bcr-2018-226897